Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Finerenone.
- Who it may be relevant to
- Registry conditions: IgA Nephropathy (IgAN). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Russia
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
: IgA-nephropathy is the most common glomerulonephritis with the unfavorable prognosis in patients with persistent albuminuria. Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist that has demonstrated efficacy in reducing albuminuria in patients with CKD and type 2 diabetes in two major trials, FIGARO-DKD and FIDELIO. This finding supported the approval of finerenone by the U.S. Food and Drug Administration (FDA) for the treatment of chronic kidney disease (CKD). A subgroup analysis in the pooled FIDELITY trial demonstrated that in patients with CKD stages 1-4 and type 2 diabetes (T2D), the cardio- and nephroprotective effects of finerenone were independent of concomitant therapy with SGLT-2 inhibitors or GLP-1 receptor agonists. Thus, the role of finerenone in slowing CKD progression in T2D can be considered well-established. Given its albuminuria-reducing effects, finerenone is being investigated in multiple trials, including studies on non-diabetic kidney disease and IgA nephropathy, though no published results are available yet. In this trial finerenone will be used as a nephroprotective agent above standard treatment in terms of assessing adverse events and potential efficacy.
Interventions
- Drug Finerenone
Finerenone is a new nonsteroidal mineralocorticoid receptor antagonist. Planned dose - 10 mg/day
Primary outcome measures
- Median change in albuminuria from baseline [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- Adults (> 18 years) with the primary IgAN diagnosed by kidney biopsy;
- Treatment with stable doses of iRAS or/and iSGLT2 inhibitors for at least 3 months prior inclusion into the trial;
- Blood pressure < 140/90 mm Hg
- 24-hour urinary albumin excretion > 300 mg
Exclusion criteria
- Kidney transplantation in medical history
- Chronic hepatic disease, including hepatitis, malignant tumor, active malignancy;
- Heart failure with ejection fraction <40%;
- Acute myocardial infarction and/or stroke less then 3 months before including in trial;
- Presence ANCA in serum
- Ongoing immunosuppressive treatment
- eGFR < 20 ml/min
- Pregnancy and breastfeeding
- Uncontrolled blood pressure
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Russia · 1 center
- Botkin Hospital — Moscow
Identifiers
NCT: NCT07056595 · IEC-6/13052025